Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus

被引：33

作者：

Aucken, HM

Warner, M

Ganner, M

Johnson, AP

Richardson, JF

Cookson, BD

Livermore, DM

机构：

[1] Cent Publ Hlth Lab, Lab Hosp Infect, London NW9 5HT, England

[2] Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2000年 / 46卷 / 04期

关键词：

D O I：

10.1093/jac/46.4.639-a

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：639 / 640

页数：2

共 6 条

[1] Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [J].

Hiramatsu, K ;

Hanaki, H ;

Ino, T ;

Yabuta, K ;

Oguri, T ;

Tenover, FC .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :135-136

[2] First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital [J].

Ploy, MC ;

Grélaud, C ;

Martin, C ;

de Lumley, L ;

Denis, F .

LANCET, 1998, 351 (9110) :1212-1212

[3] Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides [J].

Tenover, FC ;

Lancaster, MV ;

Hill, BC ;

Steward, CD ;

Stocker, SA ;

Hancock, GA ;

O'Hara, CM ;

Clark, NC ;

Hiramatsu, K .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (04) :1020-1027

[4]

Tenover Fred C., 2000, Clinical Microbiology Newsletter, V22, P49, DOI 10.1016/S0196-4399(00)88583-9

[5]

1999, SCIEI WEEKLY REPORTS, V33, P153

[6]

2000, MORBICITY MORTALITY, V48, P1165

← 1 →